Stocks

Alembic Pharma: USFDA nod adds strength

| Updated on November 20, 2018 Published on November 20, 2018

Alembic Pharmaceuticals on Tuesday said it has received approval from the US FDA to market Vardenafil Hydrochloride orally disintegrating tablets, used to treat erectile dysfunction. The drug is therapeutically equivalent to Bayer Healthcare Pharmaceuticals’ Staxyn, Alembic said. Alembic had previously received tentative approval for this product from the USFDA. The tablets have an estimated market size of $8 million in calendar year 2017.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on November 20, 2018
This article is closed for comments.
Please Email the Editor